Over the last couple of weeks there have been several developments with regard to a potential coronavirus vaccine.
On 16 November, Moderna Inc declared that its experimental vaccine is 94.5% effective in preventing COVID-19 based on interim data from a late-stage trial. This follows on from Pfizer’s announcement on 12 November when it affirmed a 90 per cent effectiveness rate in late-stage clinical trials. As reported by Reuters, Soumya Swaminathan, the WHO’s chief scientist, noted that the Pfizer and Moderna candidate vaccines both use mRNA technology and appear to achieve high efficacy.
“But there are many, many questions still remaining about the duration of protection, the impact on...
Already a subscriber? Log in
Subscribe for just $2 a week
Try a month of The Spectator Australia absolutely free and without commitment. Not only that but – if you choose to continue – you’ll pay just $2 a week for your first year.
- Unlimited access to spectator.com.au and app
- The weekly edition on the Spectator Australia app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Or
Comments
Don't miss out
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
SUBSCRIBEAlready a subscriber? Log in